First-of-its-kind genomic test predicts benefit from hormone therapy added to radiation for recurrent prostate cancer

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery—the first predictive biomarker in this setting.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup